Latest Lead News

Wrkr Ltd has completed a $15 million placement to fund key growth initiatives and compliance upgrades ahead of new superannuation regulations.

Orbital Corporation has denied any undisclosed information behind its recent share price jump, attributing market interest to strategic leadership appointments aimed at expanding its UAV propulsion business.

FBR Limited has raised A$2 million through a share placement and purchase plan, complementing a $20 million subscription facility, to fund new robotic products, strategic partnerships, and debt repayment.

Magnetite Mines Limited has announced a pro rata renounceable rights issue aiming to raise up to $2.65 million to advance its flagship Razorback iron ore project. The capital raise includes free attaching options and is partially underwritten, supporting key development milestones and strategic partnerships.

Iress Ltd confirms early-stage discussions with Blackstone and Thoma Bravo amid acquisition speculation, following a withdrawn A$10.50 per share offer from Blackstone.

Neuren Pharmaceuticals has added SYNGAP1-related disorder to its NNZ-2591 development program following encouraging pre-clinical findings, targeting a rare condition with no approved treatments.

PYC Therapeutics has escalated dosing to the highest level in its Phase 1a trial of PYC-003 and begun dosing patients with Polycystic Kidney Disease, marking key progress toward regulatory milestones.

Piedmont Lithium reported strong Q2 2025 operational results with record production at North American Lithium and $11.9 million revenue, while shareholder voting on its merger with Sayona Mining has been adjourned to August 11.

Vection Technologies has reported its first positive underlying EBITDA for FY2025, driven by strong growth in its Defence sector. The company sets ambitious FY2026 revenue targets of $70 million, underpinned by a robust $50 million sales pipeline and cutting-edge AI and spatial computing solutions.

Pinnacle Minerals Limited has launched a new options prospectus offering nearly 40 million options, potentially raising $3.18 million if exercised. The options carry an exercise price of $0.08 and expire in 2028, aiming to reward shareholders and fulfill placement obligations.

AVITA Medical reported a 21% increase in Q2 commercial revenue to $18.4 million and narrowed its net loss, yet faces a reimbursement hurdle that forced a downward revision of full-year guidance. The company highlights clinical progress and strategic board appointments as it navigates payment challenges.

Fortescue has secured a landmark RMB 14.2 billion syndicated term loan, marking the first such facility by an Australian corporate and underscoring its deepening ties with China to support its decarbonisation goals.